Isabel Barragan

Isabel Barragan

Affiliated to Research
Visiting address: Solnavägen 9, Biomedicum, 17165 Solna
Postal address: C3 Fysiologi och farmakologi, C3 FyFa Individanpassad medicin och läkemedelsutveckling, 171 77 Stockholm
Part of:

About me

  • Dr Isabel Barragan is Assistant Professor and group leader of the research
    group “Pharmacoepigenetics”.
    Isabel Barragan graduated with a Master of Pharmacy from the University of
    Seville, Spain, and achieved her PhD Degree and European Doctorate in
    Molecular Medicine for her research on the genetic basis of Inherited Retinal
    Dystrophies, with emphasis on autosomal recessive RP (arRP), which is an
    important cause of blindness worldwide. The result of this research was the
    identification and annotation of EYS, commonly mutated in arRP, which stands
    out as the first major gene reported for this inherited blindness and the
    largest eye-specific gene identified so far.
    In 2007 she became a Postdoctoral Researcher at the Clinical Genetics,
    Fertility and Fetal Therapy Unit of University Hospitals Virgen del Rocio.
    During this period, she was dedicated to identify the impact of EYS in
    different populations.
    In 2011 she moved to Stockholm to join the Department of Physiology and
    Pharmacology at Karolinska Institutet, where she focused on the
    implementation and characterisation of in vitro models for drug toxicity
    evaluation and in the identification of pharmacogenetic biomarkers in diverse
    disease conditions. As a Marie Curie Career Integration Grants fellow, she
    incorporated the study of epigenetic regulation of genes important for drug
    metabolism and action to the search for new biomarkers of interindividual
    variation in treatment response.
    Her unique background that combines Pharmacology, Human Genetics, and Liver
    Epigenetics, has allowed her to open her own line of investigations based on
    Medical Omics research to understand and overcome the lack of efficacy of
    pharmacological treatments, specifically in liver cancer.
    Dr Barragan has set up her own laboratory at the Department of Physiology
    and Pharmacology and she is appointed by the Karolinska Institutet Board of
    Research (KI- Forskarassistent ref nr 4922/12-223).

Articles

All other publications

News from KI

Events from KI